Luis Alberto Garcia Rodriguez
Overview
Explore the profile of Luis Alberto Garcia Rodriguez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jorgensen C, Boe N, Hald S, Meyer-Kristensen F, Norlen M, Ovesen C, et al.
Clin Epidemiol
. 2024 Dec;
16:837-848.
PMID: 39654831
Purpose: To estimate the strength of association between use of antithrombotics (AT) drugs with survival after spontaneous intracerebral hemorrhage (s-ICH) comparing oral anticoagulant (OAC) or platelet antiaggregants (PA) with no...
2.
Hindsholm M, Rodriguez L, Brandes A, Hallas J, Hoyer B, Moller S, et al.
JAMA Neurol
. 2024 Jun;
81(8):805-813.
PMID: 38913390
Importance: Patients with atrial fibrillation (AF) can have an ischemic stroke (IS) despite oral anticoagulant (OAC) treatment. Knowledge regarding the association between OAC discontinuation and the subsequent risk of recurrent...
3.
Brobert G, Ruigomez A, Schink T, Voss A, Herings R, Smits E, et al.
BMJ Open
. 2024 Mar;
14(3):e081348.
PMID: 38531587
Objectives: To describe opportunities and challenges experienced from the four pharmacoepidemiological database studies included in the rivaroxaban post authorisation safety study (PASS) programme and propose ways to maximise the value...
4.
Ruigomez A, Schink T, Voss A, Herings R, Smits E, Swart-Polinder K, et al.
PLoS One
. 2024 Mar;
19(3):e0298596.
PMID: 38451960
Background: The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine...
5.
Gaist D, Rodriguez L, Hallas J, Hald S, Moller S, Hoyer B, et al.
Neurology
. 2023 Aug;
101(18):e1793-e1806.
PMID: 37648526
Background And Objectives: Survivors of spontaneous intracerebral hemorrhage (ICH) may have indications for statin therapy. The effect of statins on the risk of subsequent hemorrhagic and ischemic stroke (IS) in...
6.
Boe N, Hald S, Jensen M, Kristensen L, Bojsen J, Elhakim M, et al.
JAMA Netw Open
. 2023 Apr;
6(4):e235882.
PMID: 37017964
Importance: Survivors of spontaneous (ie, nontraumatic and with no known structural cause) intracerebral hemorrhage (ICH) have an increased risk of major cardiovascular events (MACEs), including recurrent ICH, ischemic stroke (IS),...
7.
Boe N, Hald S, Jensen M, Bojsen J, Elhakim M, Florisson S, et al.
Neurology
. 2023 Mar;
100(10):e1048-e1061.
PMID: 36878720
Background And Objectives: A causal relationship between statin use and intracerebral hemorrhage (ICH) is uncertain. We hypothesized that an association between long-term statin exposure and ICH risk might vary for...
8.
Rodriguez L, Ruigomez A, Schink T, Voss A, Smits E, Swart K, et al.
Expert Opin Drug Saf
. 2023 Feb;
22(6):493-500.
PMID: 36795067
Background: The safety and effectiveness of rivaroxaban versus vitamin K antagonists (standard of care [SOC]) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) was evaluated in Europe. Research...
9.
Gaist D, Hald S, Rodriguez L, Clausen A, Moller S, Hallas J, et al.
JAMA Netw Open
. 2022 Oct;
5(10):e2234215.
PMID: 36190733
Importance: Patients with stroke due to nontraumatic (spontaneous) intracerebral hemorrhage (ICH) often harbor vascular risk factors and comorbidities, but it is unclear which major adverse cardiovascular events (MACEs) occur more...
10.
Gonzalez-Perez A, Roberts L, Vora P, Saez M, Brobert G, Fatoba S, et al.
BMJ Open
. 2022 Jun;
12(6):e059311.
PMID: 35654463
Objectives: To investigate effects of appropriately and inappropriately dosed apixaban/rivaroxaban versus warfarin on effectiveness and safety outcomes in patients with non-valvular atrial fibrillation (NVAF). Design: Cohort study with nested case-control...